Grail (GRAL) news
Recent news
Alamar Biosciences names former Grail CEO Bob Ragusa to board of directors and expands leadership team
AInvest Wire · Oct 5, 2026Grail Inc shares erase earlier gains to fall 0.5%
Grail Inc (GRL) shares reversed earlier gains, closing down 0.5% on September 24, 2026, despite a brief rally earlier in the session. The stock had initially risen on positive momentum from recent developments in the company’s oncology diagnostics pipeline, but the gains were short-lived as market…
AInvest Wire · Sep 24, 2026Grail shares resume trading, rise as much as 7.8%
AInvest Wire · Sep 24, 2026US FDA advisers vote 6-4 that Grail's Galleri is effective for proposed use in multi-cancer screening test
A panel of advisers to the U.S. Food and Drug Administration (FDA) has voted 6-4 to conclude that Grail’s Galleri test is effective for its proposed use as a multi-cancer screening tool [1]. The test, which analyzes blood samples for DNA fragments associated with over 50 types of cancer, is…
AInvest Wire · Sep 23, 2026US FDA advisers back safety of Grail's Galleri multi-cancer screening test
A panel of advisers to the U.S. Food and Drug Administration (FDA) has endorsed the safety of Grail Inc.'s Galleri multi-cancer early detection test, signaling a potential regulatory milestone for the company. The test, which analyzes blood samples for DNA fragments associated with over 50 types of…
AInvest Wire · Sep 23, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.